{"hands_on_practices": [{"introduction": "The term \"multidrug-resistant\" (MDR) is fundamental in clinical microbiology, yet its precise meaning is often misunderstood. Classifying an isolate like *Pseudomonas aeruginosa* as MDR is not simply about counting the number of antibiotics it resists; it involves a systematic approach based on non-susceptibility across distinct antimicrobial categories. This practice [@problem_id:4655423] challenges you to apply the standardized international definition of MDR to a clinical scenario, helping you distinguish between individual isolate classification and population-level statistics from an antibiogram.", "problem": "A hospital antibiogram reports Pseudomonas aeruginosa susceptibility rates of piperacillin-tazobactam $45\\%$, cefepime $50\\%$, ciprofloxacin $35\\%$, and amikacin $70\\%$. An individual clinical isolate from a patient is laboratory-confirmed as non-susceptible (resistant or intermediate) to piperacillin-tazobactam, cefepime, and ciprofloxacin, with amikacin reported as susceptible. Using standardized resistance category definitions for Pseudomonas aeruginosa, determine whether this isolate meets the Multidrug-Resistant (MDR) classification and justify your choice. Your reasoning must start from the foundational definition that MDR is determined by non-susceptibility across antimicrobial categories rather than by population-level susceptibility percentages, and it must correctly map each drug to its antimicrobial category. Select the single best answer.\n\nA. The isolate meets the Multidrug-Resistant (MDR) definition because it is non-susceptible to at least one agent in three distinct anti-pseudomonal categories (anti-pseudomonal penicillins with beta-lactamase inhibitors, anti-pseudomonal cephalosporins, and fluoroquinolones), irrespective of the $70\\%$ amikacin susceptibility rate in the antibiogram.\n\nB. The isolate does not meet the Multidrug-Resistant (MDR) definition because amikacin remains susceptible and the antibiogram shows $70\\%$ susceptibility, so there is still an active agent.\n\nC. The isolate is Extensively Drug-Resistant (XDR) because it is non-susceptible to three agents, which is sufficient to meet XDR criteria.\n\nD. The isolate cannot be classified without computing a joint probability of non-susceptibility, for example $(1-0.45)\\times(1-0.50)\\times(1-0.35)$, because antibiogram percentages must be converted to a combined risk before applying MDR criteria.", "solution": "Begin from the standardized, widely accepted definitions for acquired resistance phenotypes (Magiorakos et al., 2012), which are foundational rules used in medical microbiology:\n\n1. Multidrug-Resistant (MDR) is defined as non-susceptibility to at least one agent in $\\geq 3$ antimicrobial categories.\n2. Extensively Drug-Resistant (XDR) is defined as non-susceptibility to at least one agent in all but $\\leq 2$ categories (i.e., the isolate remains susceptible to only $2$ or fewer categories).\n3. Pan-Drug Resistant (PDR) is defined as non-susceptibility to all agents in all antimicrobial categories.\n\nFor Pseudomonas aeruginosa, the relevant anti-pseudomonal antimicrobial categories commonly include: anti-pseudomonal penicillins with beta-lactamase inhibitors (e.g., piperacillin-tazobactam), anti-pseudomonal cephalosporins (e.g., cefepime, ceftazidime), fluoroquinolones (e.g., ciprofloxacin, levofloxacin), aminoglycosides (e.g., amikacin, tobramycin), monobactams (e.g., aztreonam), carbapenems (e.g., meropenem, imipenem), and polymyxins (e.g., colistin). The precise category set used locally can vary with the testing panel, but the mapping of a tested drug to its category is fixed.\n\nApply the definitions to the isolate:\n\n- Piperacillin-tazobactam is an anti-pseudomonal penicillin plus beta-lactamase inhibitor category.\n- Cefepime is an anti-pseudomonal cephalosporin category.\n- Ciprofloxacin is a fluoroquinolone category.\n- Amikacin is an aminoglycoside category.\n\nThe isolate is non-susceptible to piperacillin-tazobactam, cefepime, and ciprofloxacin. These belong to three distinct categories. Define the count of categories with non-susceptibility as $k$. Here, $k=3$. The MDR threshold is $\\geq 3$ categories. Therefore, by direct application of the MDR definition, the isolate meets MDR criteria.\n\nIt is important to distinguish between population-level antibiogram percentages and individual isolate classification. The antibiogram values $45\\%$, $50\\%$, $35\\%$, and $70\\%$ represent the proportion of isolates in the hospital population that are susceptible to each drug. They do not determine the classification of a specific isolate, which is based on its actual laboratory susceptibility results mapped to categories. While one might compute an expected joint probability of triple non-susceptibility under an independence assumption, e.g.,\n$$\n(1-0.45)\\times(1-0.50)\\times(1-0.35) = 0.55\\times 0.50 \\times 0.65 = 0.17875 \\quad (\\text{or } 17.875\\%)\n$$\nsuch a calculation is neither required nor sufficient for classifying the individual isolate and, moreover, independence between drug susceptibilities is generally not valid due to shared mechanisms (e.g., efflux, porin loss, beta-lactamase production). Classification must use the categorical non-susceptibility count $k$.\n\nEvaluate each option:\n\nA. This option correctly states that MDR is determined by non-susceptibility in at least three distinct antimicrobial categories. It correctly maps piperacillin-tazobactam to the anti-pseudomonal penicillin plus beta-lactamase inhibitor category, cefepime to the anti-pseudomonal cephalosporin category, and ciprofloxacin to the fluoroquinolone category, giving $k=3$. It also correctly indicates that the antibiogram’s $70\\%$ susceptibility to amikacin is a population measure and does not alter classification of this specific isolate, which is susceptible to amikacin but still MDR because MDR depends on the count of categories with non-susceptibility. Verdict: Correct.\n\nB. This option incorrectly applies the MDR definition by inferring that having any active agent (amikacin) precludes MDR. The MDR definition requires non-susceptibility in $\\geq 3$ categories, not resistance to all tested agents. The presence of at least one susceptible category (aminoglycosides) means the isolate is not PDR and likely not XDR, but it does not negate MDR given $k=3$. Verdict: Incorrect.\n\nC. This option misstates the XDR definition. Non-susceptibility to three agents is not the criterion for XDR; XDR depends on non-susceptibility across categories such that the isolate remains susceptible to only $\\leq 2$ categories. In this case, the isolate is susceptible to the aminoglycoside category and potentially others not reported; with only three categories showing non-susceptibility, there is no basis to conclude XDR. Verdict: Incorrect.\n\nD. This option incorrectly asserts that classification requires converting antibiogram percentages into a joint probability calculation such as $(1-0.45)\\times(1-0.50)\\times(1-0.35)$. MDR classification is categorical and based on actual laboratory results for the isolate, not probabilistic estimates. Additionally, the independence assumption underlying such a product is biologically flawed for Pseudomonas aeruginosa due to shared resistance mechanisms. Verdict: Incorrect.", "answer": "$$\\boxed{A}$$", "id": "4655423"}, {"introduction": "Behind every MDR phenotype is a series of genetic events that alter the bacterium's biology. Modern tools like Whole Genome Sequencing (WGS) allow us to move beyond simply observing resistance to understanding its root causes at the DNA level. This exercise [@problem_id:4655365] asks you to act as a molecular detective, using WGS data to construct a causal model that explains how specific mutations and acquired genes lead to a complex resistance profile in *P. aeruginosa*, a skill essential for predicting drug efficacy and understanding the evolution of resistance.", "problem": "A mechanically ventilated patient in the intensive care unit is found to have ventilator-associated pneumonia due to Pseudomonas aeruginosa. Whole Genome Sequencing (WGS) reveals a frameshift mutation in the *oprD* gene, a nonsense mutation in the amidase regulator gene *ampD*, and acquisition of a plasmid-borne Verona Integron-encoded Metallo-beta-lactamase (VIM) gene, denoted $bla_{\\text{VIM}-2}$. The microbiology laboratory requests a mechanistic explanation that accounts for the isolate’s resistance profile and asks whether ceftolozane-tazobactam should be considered.\n\nConstruct a causal model for resistance to carbapenems and cephalosporins starting from first principles. Use the following foundational bases:\n- Central Dogma of Molecular Biology: DNA changes alter protein structure/function, which modifies cellular phenotypes relevant to antimicrobial susceptibility.\n- Transport principles: For a hydrophilic beta-lactam, net influx across the outer membrane occurs through porins; qualitatively, the inward flux $J_{\\text{in}}$ depends on porin availability and the concentration gradient, $J_{\\text{in}} \\propto P \\cdot \\Delta C$, where $P$ reflects porin-mediated permeability and $\\Delta C$ is the external-to-internal concentration difference.\n- Enzymology: Beta-lactamases catalyze hydrolysis of beta-lactam rings, lowering the active drug concentration; the hydrolysis rate $v$ for a given enzyme-substrate pair can be described by Michaelis–Menten behavior, $v = \\dfrac{k_{\\text{cat}}[E][S]}{K_M + [S]}$, where $k_{\\text{cat}}$ is the catalytic rate constant, $K_M$ the Michaelis–Menten constant, $[E]$ the enzyme concentration, and $[S]$ the substrate (antibiotic) concentration.\n- Pharmacodynamic threshold: Growth is inhibited when the intracellular active antibiotic concentration $[A]_{\\text{in}}$ exceeds the Minimum Inhibitory Concentration (MIC), denoted $C_{\\text{MIC}}$; resistance emerges when combined reductions in $J_{\\text{in}}$ and increases in hydrolysis $v$ drive $[A]_{\\text{in}} < C_{\\text{MIC}}$ over relevant time scales.\n- Class-specific properties: Ambler Class C beta-lactamase (AmpC) is chromosomally encoded in Pseudomonas aeruginosa and is derepressed when *ampD* is inactivated, increasing $[E]$ for AmpC; Ambler Class B (metallo-beta-lactamase) enzymes such as VIM hydrolyze carbapenems and cephalosporins and are not inhibited by tazobactam. Tazobactam predominantly inhibits Ambler Class A enzymes and does not inhibit metallo-beta-lactamases.\n\nBased on these principles and the WGS findings (*oprD* frameshift, *ampD* nonsense, $bla_{\\text{VIM}-2}$ acquisition), which option most accurately models the causal pathway to carbapenem and cephalosporin resistance and predicts likely susceptibility to ceftolozane-tazobactam?\n\nA. Carbapenem resistance is due solely to loss of OprD-mediated uptake; cephalosporin resistance arises from AmpC derepression; the isolate is likely susceptible to ceftolozane-tazobactam because tazobactam inhibits both AmpC and VIM.\n\nB. Carbapenem resistance is driven by VIM-mediated hydrolysis with added contribution from reduced OprD-mediated influx; cephalosporin resistance results from derepressed AmpC together with VIM-mediated hydrolysis; the isolate is likely resistant to ceftolozane-tazobactam because tazobactam does not inhibit VIM.\n\nC. Carbapenem resistance stems from efflux pump overexpression downstream of ampD mutation; cephalosporin resistance is explained by generalized outer membrane rigidity independent of porins; the isolate is likely susceptible to ceftolozane-tazobactam because ceftolozane is refractory to hydrolysis by all beta-lactamases.\n\nD. Carbapenem resistance results from altered Penicillin-Binding Proteins (PBPs) caused by oprD mutation; cephalosporin resistance is due to $bla_{\\text{VIM}-2}$ alone; the isolate is likely intermediate to ceftolozane-tazobactam because tazobactam partially inhibits metallo-beta-lactamases.\n\nE. Carbapenem resistance is explained by OprD loss and AmpC derepression without a role for $bla_{\\text{VIM}-2}$; cephalosporin susceptibility should be retained because ceftolozane resists AmpC hydrolysis; the isolate is likely susceptible to ceftolozane-tazobactam since OprD does not affect cephalosporin activity.", "solution": "### Problem Validation\n\n#### Step 1: Extract Givens\nThe problem statement provides the following information:\n- **Clinical Context:** A patient with ventilator-associated pneumonia in an intensive care unit.\n- **Pathogen:** *Pseudomonas aeruginosa*.\n- **Genetic Findings (WGS):**\n    1. A frameshift mutation in the *oprD* gene.\n    2. A nonsense mutation in the *ampD* gene.\n    3. Acquisition of a plasmid-borne Verona Integron-encoded Metallo-beta-lactamase (VIM) gene, $bla_{\\text{VIM}-2}$.\n- **Foundational Principles:**\n    1. **Central Dogma:** DNA changes alter protein structure/function, which modifies cellular phenotypes.\n    2. **Transport:** Net influx of hydrophilic beta-lactams is through porins, with flux $J_{\\text{in}} \\propto P \\cdot \\Delta C$, where $P$ is porin-mediated permeability.\n    3. **Enzymology:** Beta-lactamase hydrolysis is described by Michaelis–Menten kinetics, $v = \\dfrac{k_{\\text{cat}}[E][S]}{K_M + [S]}$.\n    4. **Pharmacodynamic Threshold:** Inhibition occurs when intracellular active antibiotic concentration $[A]_{\\text{in}}$ exceeds the Minimum Inhibitory Concentration, $C_{\\text{MIC}}$.\n    5. **Class-Specific Properties:**\n        - Ambler Class C beta-lactamase (AmpC) is chromosomally encoded in *P. aeruginosa*.\n        - Inactivation of *ampD* derepresses AmpC expression, increasing its concentration $[E]_{\\text{AmpC}}$.\n        - Ambler Class B beta-lactamases (MBLs), such as VIM, hydrolyze carbapenems and cephalosporins.\n        - Tazobactam does not inhibit MBLs (Class B enzymes).\n\n#### Step 2: Validate Using Extracted Givens\n- **Scientific Grounding:** The problem is firmly grounded in established principles of medical microbiology and bacterial genetics. The described mutations and acquired genes (*oprD* loss, *ampD* inactivation leading to AmpC derepression, and $bla_{\\text{VIM}}$ acquisition) are all classic, well-documented mechanisms of resistance in *P. aeruginosa*. The provided physical and biochemical principles (transport, enzymology) are standard textbook models. The properties of the antibiotic classes and inhibitors (carbapenems, cephalosporins, tazobactam, VIM, AmpC) are factually correct.\n- **Well-Posed:** The problem provides a clear set of genetic findings and a framework of biophysical principles. It asks for a causal model and a prediction, a task that has a unique, logical solution derivable from the premises. The information is sufficient and self-consistent.\n- **Objective:** The language is technical, precise, and devoid of subjectivity or bias.\n\n#### Step 3: Verdict and Action\nThe problem statement is valid. It is scientifically sound, well-posed, objective, and complete. I will proceed with the solution.\n\n### Solution Derivation\n\nThe task is to construct a causal model explaining the resistance phenotypes based on the provided genotypic data and first principles, and to predict the activity of ceftolozane-tazobactam.\n\n**1. Analysis of Carbapenem Resistance**\n- **Principle:** Resistance occurs when the intracellular antibiotic concentration, $[A]_{\\text{in}}$, is kept below the critical threshold, $C_{\\text{MIC}}$. This can be achieved by decreasing influx ($J_{\\text{in}}$) or increasing removal/hydrolysis ($v$).\n- **Mechanism 1 (Influx):** The WGS reveals a frameshift mutation in *oprD*. OprD is the primary porin for carbapenem entry into the periplasm of *P. aeruginosa*. A frameshift mutation results in a non-functional protein. According to the transport principle, $J_{\\text{in}} \\propto P \\cdot \\Delta C$, the loss of OprD drastically reduces the permeability $P$ for carbapenems, thereby decreasing the influx $J_{\\text{in}}$.\n- **Mechanism 2 (Hydrolysis):** The isolate has acquired $bla_{\\text{VIM}-2}$. This gene encodes VIM-2, a Verona Integron-encoded Metallo-beta-lactamase (MBL), which belongs to Ambler Class B. The problem states that Class B enzymes hydrolyze carbapenems. This introduces a potent hydrolytic activity $v$ against carbapenems in the periplasm, where $v = \\dfrac{k_{\\text{cat}}[E]_{\\text{VIM-2}}[S]_{\\text{carbapenem}}}{K_M + [S]_{\\text{carbapenem}}}$.\n- **Causal Model for Carbapenems:** The combination of severely reduced influx (due to OprD loss) and potent enzymatic hydrolysis (due to VIM-2 production) will work synergistically to keep the periplasmic and intracellular concentration of carbapenems far below $C_{\\text{MIC}}$. The AmpC derepression (see below) generally has a negligible effect on carbapenems compared to MBLs. Thus, high-level resistance to carbapenems is the definitive outcome.\n\n**2. Analysis of Cephalosporin Resistance**\n- **Mechanism 1 (Hydrolysis - AmpC):** The WGS shows a nonsense mutation in *ampD*. The *ampD* gene product normally represses the expression of the chromosomal *ampC* gene. A nonsense mutation leads to a non-functional AmpD protein, which in turn leads to the derepression (high-level constitutive expression) of AmpC. AmpC is a Class C cephalosporinase. This significantly increases the concentration of the enzyme, $[E]_{\\text{AmpC}}$, leading to a high rate of hydrolysis ($v$) for many cephalosporins.\n- **Mechanism 2 (Hydrolysis - VIM):** The acquired $bla_{\\text{VIM}-2}$ gene product, VIM-2, is also stated to hydrolyze cephalosporins. This provides a second, powerful mechanism for cephalosporin degradation.\n- **Causal Model for Cephalosporins:** The isolate possesses two potent hydrolytic enzymes against cephalosporins: the derepressed chromosomal AmpC and the acquired MBL VIM-2. The combined enzymatic activity will be very high, ensuring that the intracellular concentration of most cephalosporins remains well below their respective $C_{\\text{MIC}}$. This predicts broad resistance to this class of antibiotics.\n\n**3. Prediction for Ceftolozane-Tazobactam**\n- **Ceftolozane:** This is an oxyimino-cephalosporin specifically designed to be a poor substrate for AmpC and to evade efflux in *P. aeruginosa*. In an isolate with only AmpC derepression, it would likely remain active.\n- **Tazobactam:** This is a beta-lactamase inhibitor. The problem correctly states that tazobactam *does not inhibit* Ambler Class B metallo-beta-lactamases such as VIM.\n- **Combined Effect:** The isolate produces VIM-2. Since tazobactam cannot inhibit VIM-2, the VIM-2 enzyme will be free to hydrolyze ceftolozane. MBLs like VIM have a very broad substrate spectrum that includes advanced-generation cephalosporins like ceftolozane. Therefore, the hydrolytic activity of VIM-2 will degrade ceftolozane, preventing it from reaching its target PBPs at concentrations above $C_{\\text{MIC}}$.\n- **Prediction:** The isolate is predicted to be **resistant** to ceftolozane-tazobactam due to the uninhibited hydrolytic activity of the VIM-2 MBL.\n\n### Option-by-Option Analysis\n\n**A. Carbapenem resistance is due solely to loss of OprD-mediated uptake; cephalosporin resistance arises from AmpC derepression; the isolate is likely susceptible to ceftolozane-tazobactam because tazobactam inhibits both AmpC and VIM.**\n- This option incorrectly states that carbapenem resistance is *solely* due to OprD loss, ignoring the critical role of the VIM-2 carbapenemase. It also incorrectly claims that tazobactam inhibits VIM. As per the problem statement and known microbiology, tazobactam does not inhibit MBLs.\n- **Verdict: Incorrect.**\n\n**B. Carbapenem resistance is driven by VIM-mediated hydrolysis with added contribution from reduced OprD-mediated influx; cephalosporin resistance results from derepressed AmpC together with VIM-mediated hydrolysis; the isolate is likely resistant to ceftolozane-tazobactam because tazobactam does not inhibit VIM.**\n- This option correctly identifies the dual mechanisms for carbapenem resistance (VIM-2 hydrolysis and OprD loss). It correctly identifies the dual mechanisms for cephalosporin resistance (AmpC derepression and VIM-2 hydrolysis). It makes the correct prediction about ceftolozane-tazobactam resistance and provides the correct underlying reason (tazobactam does not inhibit VIM).\n- **Verdict: Correct.**\n\n**C. Carbapenem resistance stems from efflux pump overexpression downstream of ampD mutation; cephalosporin resistance is explained by generalized outer membrane rigidity independent of porins; the isolate is likely susceptible to ceftolozane-tazobactam because ceftolozane is refractory to hydrolysis by all beta-lactamases.**\n- This option introduces mechanisms (efflux linked to *ampD*, membrane rigidity) that are not the primary consequences of the given genetic changes and ignores the explicit findings (*oprD* loss, $bla_{\\text{VIM}-2}$). It makes a factually incorrect claim that ceftolozane is refractory to *all* beta-lactamases; it is known to be hydrolyzed by MBLs.\n- **Verdict: Incorrect.**\n\n**D. Carbapenem resistance results from altered Penicillin-Binding Proteins (PBPs) caused by oprD mutation; cephalosporin resistance is due to $bla_{\\text{VIM}-2}$ alone; the isolate is likely intermediate to ceftolozane-tazobactam because tazobactam partially inhibits metallo-beta-lactamases.**\n- This option incorrectly links the *oprD* gene (a porin) to PBPs (cell wall synthesis enzymes). It also incorrectly attributes cephalosporin resistance *solely* to $bla_{\\text{VIM}-2}$, ignoring the AmpC derepression. Finally, it falsely claims that tazobactam partially inhibits MBLs.\n- **Verdict: Incorrect.**\n\n**E. Carbapenem resistance is explained by OprD loss and AmpC derepression without a role for $bla_{\\text{VIM}-2}$; cephalosporin susceptibility should be retained because ceftolozane resists AmpC hydrolysis; the isolate is likely susceptible to ceftolozane-tazobactam since OprD does not affect cephalosporin activity.**\n- This option incorrectly ignores the major role of $bla_{\\text{VIM}-2}$ in carbapenem resistance. It incorrectly predicts cephalosporin susceptibility by ignoring the hydrolytic activity of VIM-2 against ceftolozane. Its overall conclusion of susceptibility to ceftolozane-tazobactam is therefore flawed.\n- **Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "4655365"}, {"introduction": "Identifying an antibiotic as \"susceptible\" in a lab report is only the first step; ensuring it will be effective in a patient requires a quantitative approach. The principles of pharmacokinetics and pharmacodynamics (PK/PD) provide the tools to connect drug dosage, patient-specific factors, and the pathogen's susceptibility. This problem [@problem_id:4655349] provides a hands-on opportunity to calculate and interpret a key PK/PD index, the free drug area-under-the-curve to MIC ratio ($f\\mathrm{AUC}/\\mathrm{MIC}$), to determine if a ciprofloxacin regimen is likely to succeed against a challenging *P. aeruginosa* infection.", "problem": "A hospitalized patient with ventilator-associated pneumonia has an isolate identified as Pseudomonas aeruginosa exhibiting multidrug resistance, with susceptibility testing showing a minimum inhibitory concentration (MIC) for ciprofloxacin of $0.5\\,\\mathrm{mg/L}$. Pharmacokinetic sampling from the patient’s first full dosing interval indicates a $24$-hour free (unbound) area under the plasma concentration–time curve (free AUC, denoted $f\\mathrm{AUC}$) of $80\\,\\mathrm{mg\\cdot h/L}$. Minimum Inhibitory Concentration (MIC) is defined as the lowest antimicrobial concentration that prevents visible growth under standardized conditions, and the area under the curve (AUC) is defined as the time integral of drug concentration over a specified interval. For concentration-dependent antimicrobials such as fluoroquinolones, only the unbound concentration is pharmacodynamically active; therefore, the index relating exposure to potency uses the free AUC. Clinical pharmacodynamic targets for Gram-negative bacilli, including Pseudomonas aeruginosa, are commonly expressed for ciprofloxacin as a threshold on the ratio $f\\mathrm{AUC}/\\mathrm{MIC}$ over a $24$-hour interval.\n\nStarting from these definitions and the principle that only unbound drug contributes to antibacterial effect, derive the appropriate pharmacokinetic/pharmacodynamic index that combines exposure and potency for ciprofloxacin, compute its numerical value using the provided $f\\mathrm{AUC}$ and $\\mathrm{MIC}$, and then evaluate whether the conventional target $f\\mathrm{AUC}/\\mathrm{MIC} \\geq 125$ is achieved in this patient. Report the index as a pure number without units. Express the final numerical value exactly (no rounding). You may state in words whether the target is met in your reasoning, but the final answer must be the index value alone.", "solution": "The problem is first subjected to validation.\n\n**Step 1: Extract Givens**\n-   Isolate: *Pseudomonas aeruginosa* (multidrug resistant) from a patient with ventilator-associated pneumonia.\n-   Antimicrobial: Ciprofloxacin.\n-   Minimum Inhibitory Concentration (MIC): $0.5\\,\\mathrm{mg/L}$.\n-   Free Area Under the Curve ($f\\mathrm{AUC}$) over a $24$-hour interval: $80\\,\\mathrm{mg\\cdot h/L}$.\n-   Definition of MIC: \"the lowest antimicrobial concentration that prevents visible growth under standardized conditions\".\n-   Definition of Area Under the Curve (AUC): \"the time integral of drug concentration over a specified interval\".\n-   Principle: \"only the unbound concentration is pharmacodynamically active\".\n-   Pharmacodynamic Target Index: Expressed as a ratio $f\\mathrm{AUC}/\\mathrm{MIC}$ over a $24$-hour interval.\n-   Clinical Target Threshold: $f\\mathrm{AUC}/\\mathrm{MIC} \\geq 125$ for ciprofloxacin against Gram-negative bacilli.\n-   Task: Derive the index, compute its value, and evaluate against the target.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective. It is based on established principles of clinical pharmacokinetics and pharmacodynamics (PK/PD). The concepts of Minimum Inhibitory Concentration (MIC), Area Under the Curve (AUC), and the use of the free fraction of a drug ($f\\mathrm{AUC}$) are standard in antimicrobial therapy. The $f\\mathrm{AUC}/\\mathrm{MIC}$ ratio is the accepted PK/PD index for fluoroquinolones like ciprofloxacin. The provided values for MIC and $f\\mathrm{AUC}$ are clinically plausible. The problem contains all necessary information for a unique solution and has no internal contradictions or ambiguities. The terminology is precise.\n\n**Step 3: Verdict and Action**\nThe problem is deemed **valid**. A solution will be provided.\n\nThe primary objective is to derive and compute the pharmacokinetic/pharmacodynamic (PK/PD) index that links drug exposure to antimicrobial potency for ciprofloxacin. The problem statement establishes the fundamental principle that pharmacological effect is driven by the unbound, or free, drug concentration.\n\nThe measure of total drug exposure over a dosing interval, typically $24$ hours for daily dosing regimens, is the Area Under the plasma Concentration-time Curve (AUC). Since only the free drug is active, the relevant exposure metric is the free AUC, denoted $f\\mathrm{AUC}$. This is given as $f\\mathrm{AUC} = 80\\,\\mathrm{mg\\cdot h/L}$.\n\nThe measure of the pathogen's susceptibility to the antimicrobial, which is an inverse measure of the drug's potency against that specific organism, is the Minimum Inhibitory Concentration (MIC). This is the lowest concentration of the drug that inhibits visible growth of the bacterium. For the patient's isolate, this is given as $\\mathrm{MIC} = 0.5\\,\\mathrm{mg/L}$.\n\nThe PK/PD index for concentration-dependent antibiotics like ciprofloxacin aims to quantify the magnitude of exposure relative to the potency. A higher exposure is desired for a given level of bacterial susceptibility, and a more potent drug (lower MIC) requires less exposure to be effective. This relationship is best captured by a ratio of the exposure metric to the potency metric.\n\nTherefore, the appropriate PK/PD index is derived as the ratio of the $24$-hour free area under the curve to the minimum inhibitory concentration.\n$$ \\text{PK/PD Index} = \\frac{f\\mathrm{AUC}}{\\mathrm{MIC}} $$\nThis index integrates the changing drug concentration over time and scales it by the specific drug concentration required to inhibit the target pathogen.\n\nUsing the values provided in the problem statement, we can compute the numerical value of this index for the patient.\n$$ f\\mathrm{AUC} = 80\\,\\mathrm{mg\\cdot h/L} $$\n$$ \\mathrm{MIC} = 0.5\\,\\mathrm{mg/L} $$\nSubstituting these values into the derived formula for the index:\n$$ \\frac{f\\mathrm{AUC}}{\\mathrm{MIC}} = \\frac{80\\,\\mathrm{mg\\cdot h/L}}{0.5\\,\\mathrm{mg/L}} $$\nThe units of the quantities are examined to ensure dimensional consistency. The units of the numerator are $\\mathrm{mg\\cdot h/L}$ and the units of the denominator are $\\mathrm{mg/L}$. The ratio simplifies as:\n$$ \\frac{\\mathrm{mg\\cdot h/L}}{\\mathrm{mg/L}} = \\frac{\\mathrm{mg\\cdot h}}{\\mathrm{L}} \\times \\frac{\\mathrm{L}}{\\mathrm{mg}} = \\mathrm{h} $$\nThe resulting index has units of hours, representing the equivalent time the pathogen is exposed to a constant concentration equal to the MIC, scaled by the drug's concentration profile. However, the index is conventionally reported as a dimensionless or \"pure\" number, as requested.\n\nThe numerical calculation is:\n$$ \\frac{f\\mathrm{AUC}}{\\mathrm{MIC}} = \\frac{80}{0.5} = \\frac{80}{\\frac{1}{2}} = 80 \\times 2 = 160 $$\nThe calculated value of the PK/PD index is $160$.\n\nThe final part of the task is to evaluate this result against the conventional clinical target for ciprofloxacin against Gram-negative bacilli, which is stated as $f\\mathrm{AUC}/\\mathrm{MIC} \\geq 125$.\nOur calculated value is $160$.\nComparing the calculated value to the target threshold:\n$$ 160 \\geq 125 $$\nThis inequality is true. Therefore, the ciprofloxacin dosing regimen for this patient achieves the widely accepted pharmacodynamic target for likely clinical efficacy. The final answer required is the numerical value of the index itself.", "answer": "$$\\boxed{160}$$", "id": "4655349"}]}